BiotechTV

???????? ??????????: With an experienced researcher at the helm, Theragen Bio aims to leverage its sequencing and bioinformatics expertise to also develop cancer therapies. CEO Soonmyung Paik, who was a developer Oncotype Dx and the founding director of Samsung Cancer Research Institute, discusses Theragen's sequencing and bioinformatics business and how he hopes to develop cancer vaccines and targeted therapies such as against MAPK3. Full video: https://lnkd.in/gCheDNWR BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

???????????? ???????????????????? ????????: Arbutus Biopharma Corporation's CEO (interim) Michael McElhaugh summarizes IM-PROVE I phase 2a data for imdusiran in chronic hepatitis B presented earlier this week at The Liver Meeting. He describes how 25% of patients overall, and 50% of patients who had low baseline levels of hepatitis B surface antigen, saw a functional cure. Given this learning, he also discusses the potential development plan going forward. #TLM24 Full video: https://lnkd.in/g8r35dDc BiotechTV is brough to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Klein Hersh

???????????? ???????????????????? ????????: Manchester, UK based F2G, which booked a $100M financing in September, is focused on developing therapies for fungal infections. CEO Francesco Maria Lavino describes the unmet need in this area and the science behind how F2G combats it. Plus, learnings from an FDA CRL the current development and regulatory plan. Full video: https://lnkd.in/gS2jjjF9 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

???????? ??????????: Seoul based ABL Bio Inc. is emerging as a leader in bi-specific antibodies - with programs in CNS, oncology, and a unique approach to making ADCs bi-specific as well Founder & CEO Sang Hoon Lee describes the science that sets ABL apart and where he sees Korea biotech headed. Full video: https://lnkd.in/gHSY7xWr BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

???????? ??????????:?Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea. He explains the power of protein degradation, and the upside to Orum's targeted delivery approach. Plus, selling an asset to Bristol Myers Squibb, going through an IPO roadshow, and founding a social group that brings together the biotech community in Korea. Full video: https://lnkd.in/gYHj2YcP BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

???????????? ???????????????????? ????????: A discussion on treating neurodegenerative diseases with the CEO of AC Immune. Andrea Pfeifer describes the rationale for treating neurodegenerative disease with immunotherapies, and the importance of treating people at high risk early. She covers pipeline assets in areas such as Alzheimer's and Parkinson's. Plus, why developing good diagnostics is equally as important. Full video: https://lnkd.in/gR9rDaZE BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

???????????? ???????????????????? ????????: As the company gears up for its first phase 3 trials, MindMed's CEO says he sees a tailwind of regulatory support for the psychedelics space. Robert Barrow discusses MindMed's LSD based program that is going into phase 3 studies and an earlier stage R(-)-MDMA program for autism spectrum disorder. Full video: https://lnkd.in/gtfwN2Ft BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

?????? ?????????? ??????????????: Vir Biotechnology, Inc. presented data from programs for chronic hepatitis B and chronic hepatitis delta. Vir Chief Medical Officer Mark Eisner discusses the MARCH Phase 2 study results for hepaitis B, and H?pital Beaujon Professor of Hepatology Tarik Asselah discusses the SOLSTICE Phase 2 study results for hepatitis delta. Full video: https://lnkd.in/gdpQZ-Cj BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

?????????? ?????????? ?????????????????? ?????????????????? ????????????: Read how Klein Hersh partnered with a global pharmaceutical leader to build out their Drug Safety and Pharmacovigilance team supporting their burgeoning blockbuster product lines, hiring 18 highly qualified professionals in under 18 months, alleviating operational strain and supporting accelerated FDA submissions. Link: https://lnkd.in/eyi7w-PW Reach out to Dan Strauss to learn more about how Klein Hersh can work for you. #sponsored

???????? ??????????: AIGEN Sciences Inc. is using generative AI for drug discovery and development - in addition to already having 16 programs, the company earlier this year struck an ADC deal with Hanmi. CEO Jaewoo Kang, a computer scientist, describes AIGEN's computational heavy platform. Plus, he discusses three of the most advanced programs: a pan-KRAS inhibitor, USP1, and developing linkers and payloads to help Hanmi with ADCs. Full video: https://lnkd.in/gfjun49K BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh